|3Oct 1, 5:00 PM ET

Dainippon Sumitomo Pharma Co Ltd 3

3 · Roivant Sciences Ltd. · Filed Oct 1, 2021

Insider Transaction Report

Form 3
Period: 2021-10-01
Holdings
  • Common Shares

    (indirect: See Footnote)
    86,367,360
Footnotes (1)
  • [F1]Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon") directly owns 86,367,360 Common Shares. Sumitomo Dainippon is a 51.78% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Dainippon owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein.

Documents

1 file
  • 3
    doc3.xmlPrimary

    FORM 3 SUBMISSION